Puma Biotechnology (PBYI) Other Non-Current Liabilities (2019 - 2025)
Puma Biotechnology (PBYI) posted Other Non-Current Liabilities of $1.8 million for Q1 2025, up 1357.02% on a QoQ basis from $121000.0 in Q4 2024, and up 1357.02% year-over-year from $121000.0 in Q1 2024.
Puma Biotechnology (PBYI) Other Non-Current Liabilities (2019 - 2025) Analysis & Trends
Puma Biotechnology's Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $1.8 million for Q1 2025.
- Quarterly Other Non-Current Liabilities rose 1357.02% year-over-year to $1.8 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $1.8 million (up 1357.02% YoY) and the FY2024 annual result came in at $121000.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities was $1.8 million for Q1 2025 at Puma Biotechnology, up from $121000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $7.6 million in Q2 2023 and bottomed at $37000.0 in Q3 2022.
- A 5-year average of $2.4 million and a median of $756000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Other Non-Current Liabilities surged 16178.38% — and 2022, when it sank 99.39%.
- Puma Biotechnology's Other Non-Current Liabilities stood at $5.5 million in 2021, then sank by 99.32% to $37000.0 in 2022, then soared by 227.03% to $121000.0 in 2023, then changed by 0.0% to $121000.0 in 2024, then jumped by 1357.02% to $1.8 million in 2025.
- Business Quant data shows PBYI's Other Non-Current Liabilities at $1.8 million in Q1 2025, $121000.0 in Q4 2024, and $121000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Puma Biotechnology | 407.27 Mn | 368.99 Mn | 34.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.76 Mn |
| Dec 31, 2024 | 121,000.00 |
| Sep 30, 2024 | 121,000.00 |
| Jun 30, 2024 | 3.98 Mn |
| Mar 31, 2024 | 121,000.00 |
| Dec 31, 2023 | 121,000.00 |
| Sep 30, 2023 | 121,000.00 |
| Jun 30, 2023 | 7.57 Mn |
| Mar 31, 2023 | 7.48 Mn |
| Dec 31, 2022 | 37,000.00 |
| Sep 30, 2022 | 37,000.00 |
| Jun 30, 2022 | 5.38 Mn |
| Mar 31, 2022 | 756,000.00 |
| Dec 31, 2021 | 5.46 Mn |
| Sep 30, 2021 | 6.02 Mn |
| Jun 30, 2021 | 1.18 Mn |
| Mar 31, 2021 | 206,000.00 |
| Dec 31, 2020 | 6.38 Mn |
| Sep 30, 2020 | 37,000.00 |
| Jun 30, 2020 | 7.79 Mn |